Investor Overview

Overview

Tricida, Inc. , is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.

SEC Filings

Filing date Description Form View

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A View HTML

Report of unscheduled material events or corporate event

8-K View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

A statement of beneficial ownership of common stock by certain persons

SC 13G View HTML

EFFECT

EFFECT View HTML

Pre-effective amendment to an S-3 filing

S-3/A View HTML

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.